Publication

Video

Supplements and Featured Publications

Advancing Applications for Antibody-Drug Conjugates in Breast Cancer
Volume1
Issue 1

Dr. Shiller on the Role of Trastuzumab Deruxtecan in HER2+ Breast Cancer

Michelle Shiller, DO, AP/CP, MGP, discusses the role of trastuzumab deruxtecan in patients with HER2-positive breast cancer.

Michelle Shiller, DO, AP/CP, MGP, member, the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses the role of fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with HER2-positive breast cancer.

In May 2022, the FDA granted regular approval to trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti–HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within 6 months of therapy completion.

Although HER2 has long been an important biomarker in breast cancer, a deeper understanding of the biomarker is important as new agents continue to emerge, Shiller says. Data from the phase 3 DESTINY-Breast02 (NCT03523585) and DESTINY-Breast03 (NCT03529110) trials have shown that patients who historically have had good responses with trastuzumab (Herceptin) can derive a greater benefit with trastuzumab deruxtecan, Shiller adds.

HER2-positive disease is defined as HER2 overexpression of 3+ with immunohistochemistry (IHC) or HER2 amplification of 2+ with IHC/ fluorescence in situ hybridization assays. These standards are used to identify patients who can benefit from HER2-targeted therapies, Shiller concludes.

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD